Mount Sinai Cardiologists First on East Coast to Offer New Stroke Prevention Therapy for Heart Patients
New generation implant has improved safety and performance features for those with atrial fibrillation
Mount Sinai Heart is the first site on the East Coast offering a new device for stroke prevention in patients with a dangerous type of atrial fibrillation.
The implant, called “WATCHMAN FLX,” was approved in July by the U.S. Food and Drug Administration. It represents a new generation of its technology, with safety and performance upgrades. The device provides an alternative for patients who cannot take long-term blood thinners, the standard treatment for atrial fibrillation, or “AFib,” a heart rhythm disorder that increases the risk of stroke.
WATCHMAN FLX is implanted into the heart to close off the left atrial appendage, a blind pouch of heart tissue where blood clots form in patients with AFib. These clots can break off, travel in the bloodstream to the brain, and cause strokes. In this non-surgical procedure, the implant is inserted through a vein in the leg during a one-time, catheter-based procedure in the Electrophysiology Laboratory.
Vivek Reddy, MD, Director of Cardiac Arrhythmia Services for the Mount Sinai Health System, led a team of physicians including Srinivas Dukkipati, MD, and Martin Goldman, MD, for their first WATCHMAN FLX procedure at The Mount Sinai Hospital. They successfully implanted the device in an 81-year-old AFib patient who had a stroke in July while off anticoagulants due to a large leg hematoma.
“We are delighted for The Mount Sinai Hospital to be the first institution on the East Coast to offer this therapy to our atrial fibrillation patients who are not good candidates for taking blood thinners over the long term,” Dr. Reddy said. “While the older generation of the WATCHMAN device was quite good, the improved safety profile and closure rates of this newer Watchman FLX device is an even better option for our patients.”
Atrial fibrillation affects nearly 6 million Americans and makes them five times more likely to have a stroke than those with a regular heartbeat. Some patients have AFib that’s not caused by a heart valve problem, and in this population, at least 90 percent of stroke- causing clots that come from the heart are formed in the left atrial appendage. WATCHMAN FLX permanently closes off the left atrial appendage to keep blood clots from escaping and causing the stroke. This upgraded version comes in five sizes to treat a greater variety of atrial appendage sizes compared to the previous WATCHMAN device. It also includes advanced performance and safety features.
Blood-thinning medications have been the standard of care for reducing the risk for stroke in patients with atrial fibrillation, but many patients cannot tolerate these medications because of the incidence of bleeding. While these therapies have been demonstrated to be efficacious, their effectiveness is contingent upon patient adherence, as gaps in treatment can lead to stroke.
Mount Sinai was part of PINNACLE-FLX, a national clinical trial in which this new generation device was tested in 400 AFib patients. This trial completed its one-year follow-up earlier this year, and the primary data were reported at the Late-Breaking Clinical Trials Sessions of the Heart Rhythm Society in May 2020. The device proved to be both safe (with a complication rate of only 0.5 percent) and 100 percent effective in closing the left atrial appendage.
Dr. Reddy published research on the previous version of WATCHMAN in multiple journals including JAMA, The Lancet, American Heart Association’s Circulation, and the Journal of the American College of Cardiology, and demonstrated the safety/efficacy of the device, as well as showing that it is more cost effective than some anticoagulants for Medicare and Medicaid patients.
So far 30 hospitals across the country have implanted the new WATCHMAN FLX devices. More than 100,000 WATCHMAN procedures (with the pervious device) have been performed worldwide. Boston Scientific makes WATCHMAN devices and Dr. Reddy has received research grants from and serves as an unpaid consultant to the company.
About the Mount Sinai Health System
The Mount Sinai Health System is New York City's largest academic medical system, encompassing eight hospitals, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region. Mount Sinai advances medicine and health through unrivaled education and translational research and discovery to deliver care that is the safest, highest-quality, most accessible and equitable, and the best value of any health system in the nation. The Health System includes approximately 7,300 primary and specialty care physicians; 13 joint-venture ambulatory surgery centers; more than 415 ambulatory practices throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and more than 30 affiliated community health centers. The Mount Sinai Hospital is ranked on U.S. News & World Report's "Honor Roll" of the top 20 U.S. hospitals and is top in the nation by specialty: No. 1 in Geriatrics and top 20 in Cardiology/Heart Surgery, Diabetes/Endocrinology, Gastroenterology/GI Surgery, Neurology/Neurosurgery, Orthopedics, Pulmonology/Lung Surgery, Rehabilitation, and Urology. New York Eye and Ear Infirmary of Mount Sinai is ranked No. 12 in Ophthalmology. Mount Sinai Kravis Children's Hospital is ranked in U.S. News & World Report’s “Best Children’s Hospitals” among the country’s best in four out of 10 pediatric specialties. The Icahn School of Medicine is one of three medical schools that have earned distinction by multiple indicators: ranked in the top 20 by U.S. News & World Report's "Best Medical Schools," aligned with a U.S. News & World Report "Honor Roll" Hospital, and No. 14 in the nation for National Institutes of Health funding. Newsweek’s “The World’s Best Smart Hospitals” ranks The Mount Sinai Hospital as No. 1 in New York and in the top five globally, and Mount Sinai Morningside in the top 20 globally.